This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Pneumococcal Disease Complicating Influenza1
Influenza predisposes individuals to developing bacterial CAP. During each of the influenza pandemics of the 20th century, secondary bacterial pneumonia was a frequent cause of illness and death, and S. pneumoniae (pneumococcus) was reported as the most common aetiology. These findings also apply to seasonal influenza.
S. pneumoniae remains a leading cause of vaccine-preventable illness and death in the United States. Recently, pneumococcal infections have been identified as an important complication in severe and fatal cases of 2009 H1N1 influenza virus infection. Importantly, however, approximately 70 million persons with existing PPSV indications (Table) are unvaccinated (National Health Interview Survey, 2007).
Use of PPSV During the 2009 H1N1 Influenza Pandemic1
CDC’s ACIP recommends a single dose of PPSV for all people ≥65 years of age and for persons 2 through 64 years of age with certain high-risk conditions. Most people in these groups are at increased risk of pneumococcal disease as well as serious complications from influenza virus infections. Single revaccination at least 5 years after the initial vaccination is recommended for people ≥65 years who were first vaccinated before the age of 65 years. Single revaccination is also recommended for people at the highest risk of disease, such as those who have functional and anatomical asplenia, and those who have an HIV infection, AIDS or malignancy and have at least 5 years elapsed from receipt of first vaccination. All people who have existing indications for PPSV should continue to be vaccinated according to the current ACIP recommendations during the 2009 H1N1 influenza pandemic. Special emphasis should be placed on vaccinating people 2 through 64 years of age who have established high-risk conditions for pneumococcal disease; PPSV coverage among this group is low, and this group may be more likely to develop secondary bacterial pneumonia after an influenza infection. Use of PPSV among people without current indications for vaccination is not recommended at this time.
Simultaneous Administration of Pneumococcal (PPSV) and Influenza Vaccines
Pneumococcal vaccine can be given at any time during the year and may be given at the same time as the influenza vaccine. Visits for seasonal and 2009 H1N1 influenza vaccination provide a convenient time to evaluate patients for the need for pneumococcal vaccination. Persons who cannot remember if they have ever had the pneumococcal vaccine should still be vaccinated.
US ACIP Recommendations for the Use of PPSV
ACIP, Advisory Committee on Immunization Practices; AIDS, acquired immunodeficiency syndrome; CAP, community-acquired pneumonia; CDC,Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; PPSV, pneumococcal polysaccharide vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.